Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
5.77 | 2.42 | 6.75 | 5.75 | |
Current Ratio |
6.80 | 5.10 | 8.04 | 7.17 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.60) | (3.97) | (1.68) | (2.22) | |
Working Capital |
6.53 | 5.21 | 8.58 | 7.48 | |
Capital Expenditures |
— | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
6.46 | 5.15 | 8.44 | 7.34 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.84 | 0.76 | 1.01 | 0.88 | |
Average Payables |
0.52 | 0.90 | 1.03 | 1.16 | |
Average Inventory |
0.66 | 0.86 | 1.26 | 1.29 | |
Average Assets |
11.56 | 10.68 | 11.45 | 9.51 | |
Average Common Equity |
10.36 | 9.22 | 10.00 | 7.90 |
Columns are period end dates · fundamentals updated 6 Oct 2026